White House Slams 'Baseless' Claims Trump Got Exclusive Weight-Loss Drug Access
White House Slams 'Baseless' Claims Trump Got Exclusive Weight-Loss Drug Access
The White House vehemently denies reports of Donald Trump receiving special, early access to an experimental weight-loss drug. Officials label the claims 'baseless speculation.'
The White House has strongly denied claims that former President Donald Trump was the “well-connected” individual who reportedly received early, compassionate access to an experimental weight-loss drug. A spokesman for the White House dismissed these theories as “baseless speculation,” aiming to put an end to the swirling rumors.
The allegations originated from a report by STAT News, which suggested that a 79-year-old man was granted exclusive access to a new weight-loss medication from pharmaceutical giant Eli Lilly, with the approval of the Food and Drug Administration (FDA), following a request made in April. This extraordinary access was reportedly given under “compassionate use” protocols, typically reserved for patients with serious conditions who have no other treatment options.
The report did not explicitly name former President Trump, but the detail of a “79-year-old well-connected man” quickly led to widespread speculation across media and social platforms, given Trump's age and prominent public profile. However, the White House has been quick to push back against these insinuations.
In a statement, a White House representative reiterated that any suggestions linking former President Trump to this incident are entirely unfounded. The administration appears keen to distance itself from the narrative, emphasizing that the former president did not receive any such special treatment regarding experimental medications. This denial seeks to clarify the situation and counter the persistent rumors circulating online and in news outlets.
